RNF113A

Across TCGA pan-cancer cohorts, RNF113A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RNF113A data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RNF113A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNF113A expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where RNF113A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.465	0.739	.001	26	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	24	view →
LUAD	OS	Median	III,IV	0.869	0.312	.004	8	view →
UCEC	DFS	Tertile	All	0.954	0.788	.014	8	view →
CCRCC	DFS	Quartile	II,III,IV	0.887	0.198	.024	6	view →
GBM	DFS	Tertile	All	0.541	0.286	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RNF113A–HNSC (DFS)

Open the HNSC breakdown →